58 results about "Gram-positive bacterial infections" patented technology

There is described a composition comprising a therapeutically active imidazole, and derivatives thereof, and an agent active on a bacterial cell surface selected from the group consisting of one or more of colistin, nisin, D-cycloserine, fosfomycin, fosfomycin trometamol, fosfomycin disodium and polymixin B, and derivatives thereof.

The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue, under conditions where a protein-dalbavancin complex forms, or administering a protein-dalbavancin complex. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.

Dry powder vancomycin compositions and methods for administering and preparing such compositions. A composition of the present disclosure may be administered to a subject via pulmonary administration in an amount effective to treat and/or prevent a bacterial infection in the subject. Administration of an effective amount of a composition of the present disclosure may be particularly useful in treating a gram-positive bacterial infection in a subject suffering from pneumonia, cystic fibrosis, bronchiectasis, or other chronic lung disease with a bacterial infection of the subject's airway and/or lung.

The invention provides methods and compositions for treatment of bacterial infections in adult and pediatric patients. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and skin structure. Dosing regimens include multiple dose administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.

The present invention relates to the use of endotoxin neutralizing protein (ENP) and derivatives thereof as stand alone microbial inhibitors or as synergistic enhancers of antibiotics and preservatives. Compositions comprising ENP or alone or in combination with an antibiotic may be used to prevent or treat gram-negative bacterial infections, endotoxemia, septic shock, gram-positive bacterial infections, yeast infections and fungal infections. Compositions comprising ENP alone or in combination with a conventional preservative may be used as antimicrobial preservative in cosmetic or personal care preparations.

The invention provides an immunogenic molecular entity, a supramolecular assembly, and an antibody that can be used to inhibit Gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a Gram-positive bacterial infection. The invention also provides methods of inhibiting Gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a Gram-positive bacterial infection.

The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin formulations for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.

Compositions and methods are provided for treating Gram positive bacterial infection in a mammalian subject. Compositions and methods are further provided for treating Gram positive bacterial skin infection in the mammalian subject. Compositions and methods are provided that comprise administering to the mammalian subject an effective amount of a compound that activates Scd1 gene expression or activates Scd1 gene product.

Provided herein in some embodiments is a method of treating a disease or condition such as an antibiotic resistant bacterial infection, a gram negative bacterial infection, a gram positive bacterial infection, a fungal infection, protozoa, a hemorrhagic virus, such as Ebola or Dengue, or a non-hemorrhagic virus, such as a coronavirus, in a subject, comprising administering to the subject in need thereof an effective amount of a composition comprising platelets or platelet derivatives, such as freeze-dried platelets; and an incubating agent comprising one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural and artificial surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.

The present invention relates to compounds and methods of treating, preventing, or lessening the severity of drug-resistant Gram-positive bacterial infections in mammals. The compounds consist of a combination of a gyrase B inhibitor and a protein synthesis inhibitor. These compounds demonstrate antibacterial activity against drug-resistant strains of Gram-positive bacteria, and in particular, methicillin-resistant Staphylococcus aureus (MRSA). Methods for inhibiting the activity of strains of Gram-positive bacteria and methods for treating a bacterial infection caused by such organisms are described herein.

The present invention includes a method of treating or preventing a disease or disorder such as a mycobacterial infection, a Gram-positive bacterium infection, a yeast infection, an inflammatory condition, an auto-immune disorder and/or a proliferative disorder in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of at least one compound of the invention, which includes clofazimine derivatives.

The invention discloses 30% lincomycin hydrochloride injection. The ratio of the 30% lincomycin hydrochloride injection by C18H34N2O6S is 10ml:3g. A preparation method of the 30% lincomycin hydrochloride injection includes the steps: adding water for injection accounting for 50% of prescription dosage; adding benzyl alcohol with the prescription dosage; stirring and dissolving the benzyl alcohol; adding lincomycin hydrochloride with the prescription dosage; dissolving the lincomycin hydrochloride; replenishing the water for injection to reach total quantity; performing fine filtration with a 0.22 micrometer filter element; sterilizing solution by circulating steam at the temperature of 100 DEG C to obtain the 30% lincomycin hydrochloride injection. The 30% lincomycin hydrochloride injection is a bacteriostatic agent and has a bactericidal effect on highly sensitive bacteria when at high concentration. By increasing the concentration, the bactericidal effect of lincomycin on the sensitive bacteria is remarkably enhanced. Asepsis of a medicine is ensured by a final bactericidal production process without affecting stability of the medicine, and efficacy is ensured. Clinically, the 30% lincomycin hydrochloride injection is commonly used for gram positive bacterial infection, particularly, infection of penicillin-resistant bacteria sensitive to the lincomycin such as staphylocosis, streptococcicosis and mastitis, and can also be used for swine treponematosis and swine enzootic pneumonia caused by mycoplasma infection.